AstraZeneca has ended a phase 3 clinical trial of the drug volrustomig for the treatment of metastatic non-small cell lung cancer.
The trial was specifically evaluating the drug in combination with chemotherapy compared to pembrolizumab and chemotherapy in metastatic non-small cell lung cancer patients whose PD-L1 scores were less than 50%, according to an Aug. 17 news release from AstraZeneca.
After reviewing trial data, the Independent Data Monitoring Committee determined volrustomig was unlikely to meet survival outcomes, though no new safety signals were identified.
“While we are disappointed, we will learn from this trial and are determined to continue pioneering new medicines from our industry-leading pipeline in our quest to improve outcomes for patients with lung cancer,” Susan Galbraith, MD, PhD, executive vice president of oncology haematology R&D at AstraZeneca, said in the release.
Other phase 3 volrustomig trials in cervical cancer, head and neck squamous cell carcinoma and mesothelioma will continue as planned, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
